Bicycle Therapeutics (BCYC) Receivables (2018 - 2025)

Bicycle Therapeutics (BCYC) has 8 years of Receivables data on file, last reported at $35.6 million in Q4 2025.

• Quarterly Receivables changed 0.28% year-over-year to $35.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.6 million (changed 0.28% YoY) and the FY2025 annual result came in at $35.6 million, changed 0.28% from the prior year.
• Receivables retreated to $35.6 million in Q4 2025, from $46.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $76.5 million in Q1 2023 to a low of $11.4 million in Q3 2022.
• A 5-year average of $32.6 million and a median of $26.3 million in 2022 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables jumped 120.69% — and 2024, when it retreated 19.49%.
• Tracing BCYC's Receivables over 5 years: stood at $11.9 million in 2021, then jumped by 78.06% to $21.2 million in 2022, then gained by 13.35% to $24.0 million in 2023, then jumped by 48.51% to $35.7 million in 2024, then declined by 0.28% to $35.6 million in 2025.
• The last three Receivables figures came in at $35.6 million (Q4 2025), $46.4 million (Q1 2025), and $35.7 million (Q4 2024), per Business Quant data.